TanCAR7 T cells showed superior antisolid tumor activity in vivo. NSG mice (n = 6) were injected intraperitoneally with 2 × 10⁶ Raji-luciferase-GFP cells mixed with Matrigel on day −7 to establish a solid tumor xenograft animal model. On day 0, the mice were injected IV with 1 × 10⁶ CAR T cells. (A) The bioluminescence images (BLIs) indicating the mouse tumor burden at the indicated time points are representative of all experiments (n = 6 mice per group; the results were pooled from 2 independent experiments). (B) Mouse tumor burden (average radiance). (C) The percentage of CD3⁺ T cells in peripheral blood was used to evaluate the expansion of CAR T cells. Data for each mouse at the indicated time points are presented. (D) Survival analyses of mice treated with TanCAR7 T cells, NT cells, CD19 CAR T cells, or CD20 CAR T cells. P values were calculated with the log-rank Mantel-Cox test. (E-F) Mice were euthanized on day 7 after treatment. (E) Flow cytometry was used to determine the percentage of PD-1⁺TIM-3⁺ CAR T cells in peritoneal tumor tissue. (F) Paraffin tumor sections were stained with an scFv-specific probe or a granzyme B–specific probe via RNA ISH (original magnification ×100 and ×400) (left panel). The positive rates of scFV and Granzyme B are shown on the right. Data are mean ± standard deviation of 5 mice per group in 2 independent experiments. P values were calculated using a 2-tailed unpaired Student t test. *P < .05, **P < .01, ***P < .001, ****P < .0001. IFN-γ, interferon-γ; NT, nontransduced control; TNF-α, tumor necrosis factor-α.